Business Description
Trinity Biotech PLC
ISIN : US8964383066
Share Class Description:
FRA:TRB0: ADRTotal Employee Number:
287Description
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.04 | |||||
Equity-to-Asset | -0.68 | |||||
Debt-to-Equity | -1.92 | |||||
Debt-to-EBITDA | -6.45 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.06 | |||||
Beneish M-Score | -3.74 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -39.3 | |||||
3-Year EBITDA Growth Rate | 38.9 | |||||
3-Year EPS without NRI Growth Rate | 27 | |||||
3-Year FCF Growth Rate | 17.5 | |||||
3-Year Book Growth Rate | -138.1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.25 | |||||
Quick Ratio | 0.12 | |||||
Cash Ratio | 0.04 | |||||
Days Inventory | 263.85 | |||||
Days Sales Outstanding | 93.56 | |||||
Days Payable | 202.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -34.9 | |||||
Shareholder Yield % | -371.21 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 38.57 | |||||
Operating Margin % | -26.07 | |||||
Net Margin % | -85.36 | |||||
EBITDA Margin % | -48.83 | |||||
FCF Margin % | -27.87 | |||||
OCF Margin % | -13.61 | |||||
ROA % | -36.4 | |||||
ROIC % | -10.59 | |||||
3-Year ROIIC % | 1.84 | |||||
ROC (Joel Greenblatt) % | -337.24 | |||||
ROCE % | -69.91 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 3 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.21 | |||||
EV-to-EBIT | -5.85 | |||||
EV-to-EBITDA | -6.6 | |||||
EV-to-Revenue | 3.22 | |||||
EV-to-Forward-Revenue | 1.27 | |||||
EV-to-FCF | -11.57 | |||||
Price-to-GF-Value | 0.52 | |||||
Price-to-Median-PS-Value | 0.41 | |||||
Earnings Yield (Greenblatt) % | -17.08 | |||||
FCF Yield % | -156.8 | |||||
Forward Rate of Return (Yacktman) % | -69.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Trinity Biotech PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 37.632 | ||
| EPS (TTM) (€) | -1.719 | ||
| Beta | 0.7643 | ||
| 3-Year Sharpe Ratio | -0.59 | ||
| 3-Year Sortino Ratio | -0.67 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 2.12 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 2.12 - 2.12 | ||
| Shares Outstanding (Mil) | 20.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Trinity Biotech PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Trinity Biotech PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-12-23 | In 164 days | ||
| General meeting for 2026 | 2026-09-30 10:00 | In 81 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 34 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 33 days | ||
| 0.0333333:1 Stock Split | 2026-07-24 | In 12 days | ||
| First quarter earnings results for 2026 | 2026-06-16 | 2.12 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-05-01 | 2.12 (+0.00%) | ||
| Annual report for 2025 | 2026-04-30 | 2.12 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-12-23 | 2.12 (+0.00%) | ||
| General meeting for 2025 | 2025-09-30 10:00 | 2.12 (+0.00%) |
Show
Entries
Trinity Biotech PLC Frequently Asked Questions
What is Trinity Biotech PLC(FRA:TRB0)'s stock price today?
The current price of FRA:TRB0 is €2.12. The 52 week high of FRA:TRB0 is €2.12 and 52 week low is €2.12.
When is next earnings date of Trinity Biotech PLC(FRA:TRB0)?
The next earnings date of Trinity Biotech PLC(FRA:TRB0) is 2026-08-14 Est..
Does Trinity Biotech PLC(FRA:TRB0) pay dividends? If so, how much?
Trinity Biotech PLC(FRA:TRB0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Trinity Biotech PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers